NVO vs SEPN
NVO: A global healthcare leader with a deep-rooted heritage in diabetes care and a focus on treating chronic diseases through scientific innovation. SEPN: Septerna is a biotechnology company pioneering a new approach to unlock the therapeutic potential of G protein-coupled receptors (GPCRs) through oral small molecule drug discovery.
Side-by-side fundamentals
| Metric | NVO | SEPN | Edge |
|---|---|---|---|
| Price as of 2026-08-25 close | $48.66 | $41.30 | |
| Market cap as of 2026-08-26 | $207.5B | $1.9B | |
| P/E as of 2026-08-26 | 11.40 | n/a | |
| PEG as of 2026-08-26 | 16.16 | n/a | |
| Net margin as of 2026-08-26 | +35.4% | -49.9% | NVO higher |
| Gross margin as of 2026-08-26 | +80.7% | n/a | |
| Operating margin as of 2026-08-26 | +43.1% | -77.1% | NVO higher |
| ROE as of 2026-08-26 | +59.1% | -9.4% | NVO higher |
| ROA as of 2026-08-26 | +21.1% | -6.6% | NVO higher |
| Debt / equity as of 2026-08-26 | 0.63 | 0.00 | SEPN lower |
| Revenue growth (YoY) as of 2026-08-26 | +5.6% | +11790.1% | SEPN higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | +1644.5% | SEPN higher |
| Dividend yield as of 2026-08-26 | +1.0% | n/a | |
| Beta as of 2026-08-26 | 1.91 | 0.80 | |
| 1-year return as of 2026-08-25 close | -13.6% | +245.3% | SEPN higher |
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-25.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.